New hope for hard-to-treat myeloma: drug duo enters human trials
NCT ID NCT06896916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of two drugs, etentamig and iberdomide, in adults with multiple myeloma that has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combo can control the cancer. About 135 participants will take part at sites worldwide.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC, Location VUmc /ID# 267670
RECRUITINGAmsterdam, North Holland, 1081 HV, Netherlands
-
Austin Hospital /ID# 265984
RECRUITINGMelbourne, Victoria, 3084, Australia
-
Beverly Hills Cancer Center /ID# 266921
RECRUITINGBeverly Hills, California, 90211, United States
-
Blacktown Hospital /ID# 265983
RECRUITINGBlacktown, New South Wales, 2148, Australia
-
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694
RECRUITINGTours, Indre-et-Loire, 37000, France
-
Chu De Lille - Hopital Claude Huriez /ID# 270193
RECRUITINGLille, Hauts-de-France, 59037, France
-
Chu de Nice-Hopital Larchet Ii /Id# 266845
RECRUITINGNice, Alpes-Maritimes, 06202, France
-
Colorado Blood Cancer Institute /ID# 273751
RECRUITINGDenver, Colorado, 80218, United States
-
Dokkyo Medical University Hospital /ID# 271648
RECRUITINGMibu, Tochigi, 321-0293, Japan
-
Hôpital La Timone /ID# 267053
RECRUITINGMarseille, Bouches-du-Rhone, 13885, France
-
IUCT Oncopole /ID# 266391
RECRUITINGToulouse, Occitanie, 31059, France
-
Jewish General Hospital /ID# 267574
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Kumamoto University Hospital /ID# 270530
RECRUITINGKumamoto, Kumamoto, 860-8556, Japan
-
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282
RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Hospital East /ID# 268343
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
Nippon Medical School Hospital /ID# 270254
RECRUITINGBunkyo-ku, Tokyo, 113-8603, Japan
-
Oslo Universitetssykehus Ulleval /ID# 275433
RECRUITINGOslo, 0450, Norway
-
Rutgers Cancer Institute of New Jersey /ID# 266833
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Sir Charles Gairdner Hospital /ID# 265985
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Swedish Medical Center - Seattle /ID# 268052
RECRUITINGSeattle, Washington, 98104, United States
-
The Alfred Hospital /ID# 265981
RECRUITINGMelbourne, Victoria, 3004, Australia
-
The Cancer Institute Hospital Of JFCR /ID# 268342
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
Universitair Medisch Centrum Utrecht /ID# 267660
RECRUITINGUtrecht, 3584 CX, Netherlands
-
University Health Network_Princess Margaret Cancer Centre /ID# 275636
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
University Of North Carolina Health Care - Hillsborough Campus /ID# 278230
RECRUITINGHillsborough, North Carolina, 27278, United States
-
Washington University /ID# 266972
RECRUITINGSt Louis, Missouri, 63110, United States
-
Wollongong Hospital /ID# 265625
RECRUITINGWollongong, New South Wales, 2500, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact